TW201940512A - 具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體 - Google Patents
具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體 Download PDFInfo
- Publication number
- TW201940512A TW201940512A TW108102958A TW108102958A TW201940512A TW 201940512 A TW201940512 A TW 201940512A TW 108102958 A TW108102958 A TW 108102958A TW 108102958 A TW108102958 A TW 108102958A TW 201940512 A TW201940512 A TW 201940512A
- Authority
- TW
- Taiwan
- Prior art keywords
- binding polypeptide
- isolated
- domain
- amino acid
- isolated binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201940512A true TW201940512A (zh) | 2019-10-16 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108102958A TW201940512A (zh) | 2018-01-26 | 2019-01-25 | 具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (https=) |
| EP (1) | EP3743441A1 (https=) |
| JP (3) | JP7399880B2 (https=) |
| KR (2) | KR102748986B1 (https=) |
| CN (2) | CN111788221B (https=) |
| AU (2) | AU2019212638B2 (https=) |
| BR (1) | BR112020015006A2 (https=) |
| CA (1) | CA3089602A1 (https=) |
| CO (1) | CO2020010269A2 (https=) |
| IL (2) | IL318916A (https=) |
| MX (2) | MX2020007882A (https=) |
| MY (1) | MY203898A (https=) |
| PH (1) | PH12020551134A1 (https=) |
| SG (1) | SG11202006905YA (https=) |
| TW (1) | TW201940512A (https=) |
| WO (1) | WO2019147973A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| EP4004039A2 (en) * | 2019-07-25 | 2022-06-01 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| US11434276B2 (en) * | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
| MX2023004933A (es) * | 2020-10-29 | 2023-06-06 | Formycon Ag | Proteinas de fusion de ace2 y usos de las mismas. |
| US12297273B2 (en) | 2021-05-27 | 2025-05-13 | Sanofi | Fc variant with enhanced affinity to Fc receptors and improved thermal stability |
| MX2024002150A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Anticuerpos y proteinas de fusion de igg con una semivida prolongada. |
| WO2023244276A2 (en) * | 2021-10-13 | 2023-12-21 | The Wistar Institute Of Anatomy And Biology | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS |
| IL317227A (en) | 2022-05-27 | 2025-01-01 | Sanofi Sa | Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| KR20250094703A (ko) | 2022-10-25 | 2025-06-25 | 아블린쓰 엔.브이. | 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드 |
| AR131281A1 (es) | 2022-12-05 | 2025-03-05 | Sanofi Sa | Proteínas de unión al receptor de transferrina |
| US20250154262A1 (en) | 2023-10-25 | 2025-05-15 | Ablynx N.V. | Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| HU230769B1 (hu) * | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| KR20070057839A (ko) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2373689A1 (en) * | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| HRP20160422T1 (hr) * | 2009-12-23 | 2016-05-20 | Synimmune Gmbh | Protutijela protiv flt3 postupci njihove upotrebe |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| RU2687043C2 (ru) * | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RS59340B1 (sr) * | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| SG11201900616UA (en) * | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
-
2019
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
-
2020
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY203898A (en) | 2024-07-23 |
| KR20250008975A (ko) | 2025-01-16 |
| EP3743441A1 (en) | 2020-12-02 |
| BR112020015006A2 (pt) | 2020-12-29 |
| KR102748986B1 (ko) | 2025-01-02 |
| AU2019212638A1 (en) | 2020-09-17 |
| CN111788221A (zh) | 2020-10-16 |
| MX2020007882A (es) | 2020-12-03 |
| IL276286A (en) | 2020-09-30 |
| US20190263934A1 (en) | 2019-08-29 |
| NZ767453A (en) | 2025-03-28 |
| CO2020010269A2 (es) | 2020-12-10 |
| JP2026021377A (ja) | 2026-02-10 |
| IL276286B1 (en) | 2025-03-01 |
| RU2020128177A (ru) | 2022-02-28 |
| SG11202006905YA (en) | 2020-08-28 |
| CN119350481A (zh) | 2025-01-24 |
| MX2025009543A (es) | 2025-09-02 |
| KR20200115568A (ko) | 2020-10-07 |
| IL318916A (en) | 2025-04-01 |
| JP7399880B2 (ja) | 2023-12-18 |
| JP2021511830A (ja) | 2021-05-13 |
| CN111788221B (zh) | 2026-02-13 |
| AU2019212638B2 (en) | 2025-04-03 |
| CA3089602A1 (en) | 2019-08-01 |
| PH12020551134A1 (en) | 2021-05-31 |
| IL276286B2 (en) | 2025-07-01 |
| AU2025204826A1 (en) | 2025-07-17 |
| JP2024026255A (ja) | 2024-02-28 |
| WO2019147973A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111788221B (zh) | 具有与FcRn增强的结合及延长的半衰期的Fc变体 | |
| TWI809562B (zh) | 抗tau抗體及其用途 | |
| JP7165996B2 (ja) | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 | |
| CN114466663B (zh) | 以FcRn拮抗剂治疗抗体介导的障碍的方法 | |
| TW202227487A (zh) | 與ｖｅｇｆ—ａ及ａｎｇ２結合之抗體及其使用方法 | |
| AU2020358898B2 (en) | Hybrid antibody | |
| KR20260047593A (ko) | 최적화된 Fc 분자 | |
| RU2795592C2 (ru) | Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения | |
| BR122024014725A2 (pt) | Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos | |
| TW202607021A (zh) | 結合ｔｓｌｐ之抗體及使用方法 | |
| HK40086991A (zh) | 与vegf-a和ang2结合的抗体及其使用方法 | |
| BR122024019353A2 (pt) | Anticorpos anti-pser413 tau, anticorpos humanizados, molécula de ácido nucleico, vetor ou plasmídeo, composições compreendendo os mesmos, células hospedeiras, métodos para preparação dos referidos anticorpos, uso dos mesmos e agente para tratar ou prevenir demência |